GlaxoSmithKline to Pay $90 Million to States to Settle Claims Related to Marketing of Diabetes Drug
November 15, 2012
Attorney General Michael C. Geraghty today joined 37 other attorneys general in announcing a $90 million settlement with GlaxoSmithKline LLC (GSK) resolving allegations that the company unlawfully promoted its diabetes drug, Avandia.
The Attorneys General allege that GSK engaged in unfair and deceptive practices by misrepresenting Avandia’s cardiovascular risks and safety profile.
As part of the agreement, GSK agreed to change how it markets and promotes diabetes drugs. GSK may not:
- Make any false, misleading, or deceptive claims about any diabetes drug;
- Make comparative safety claims not supported by appropriate evidence or clinical experience;
- Promote investigational drugs; or
- Misuse statistics or misrepresent the nature or significance of clinical trials.
For eight years GSK also be required to post summaries of certain studies and clinical trials of diabetes drugs.
Under the settlement, Alaska will receive $1,185,554. This payment is in addition to the $1.4 million Alaska received in a previous settlement with GSK resolving healthcare fraud claims.
For more information about the settlement, please contact Assistant Attorney General Cynthia Drinkwater at (907) 269-5200.
# # #